Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spruce Biosciences Inc SPRB

Healthcare Biotechnology
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is... see more

Recent & Breaking News (NDAQ:SPRB)

Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates

Business Wire March 22, 2021

Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society's 2021 Annual Meeting

Business Wire March 17, 2021

Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society's 2021 Annual Meeting

Business Wire March 2, 2021

Spruce Biosciences to Participate in Upcoming Investor Conferences

Business Wire February 17, 2021

Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021

Business Wire January 6, 2021

Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

Business Wire December 17, 2020

Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 18, 2020

Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

Business Wire November 4, 2020

Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire October 14, 2020